Type-2 Diabetes Competitive Intelligence Report Offered by Austin Research Group

Business Wire, June 18, 2008

PLEASANTON, Calif. -- It is estimated that diabetes affects more than 18 million people in the United States and approximately 194 million adults worldwide. The World Health Organization projects that the number of people with diabetes will double to 366 million by 2030, presenting a lucrative commercial opportunity to drug development companies.

Austin Research Group has just released their latest report entitled "Therapeutic Clinical Intelligence: Type-2 Diabetes Pipeline" which profiles the 35 most promising compounds in mid-to-late stage development for the treatment of Type-2 diabetes. The assessment provides decision makers with insight into the crowded R&D environment for Type-2 diabetes therapeutics and analyzes clinical intelligence on key competitors that have the potential to impact the market over the next five to seven years.

This report contains synthesized information and analysis of clinical activities for compounds in development for Type-2 diabetes. Our detailed evaluations of completed and ongoing studies capture key elements of competitor trials including:

* Trial design

* Start and end dates (trial duration)

* Study size and patient type

* Number of participating sites

* Dosing regimen

* Endpoints

* Safety and efficacy results

For more information or to purchase this report, please visit www.austinresearchgroup.com or email Laurel Austin at laurelp@austin-research.com.

About Austin Research Group

Austin Research Group, founded in 2006, is a research & consulting firm that provides clinical & commercial competitive intelligence services to biotechnology and pharmaceutical companies. For more information, please visit our web site at www.austinresearchgroup.com.